EGFR G796D mutation mediates resistance to osimertinib

Di Zheng; Min Hu; Yu Bai; Xuehua Zhu; Xuesong Lu; Chunyan Wu; Jiying Wang; Li Liu; Zheng Wang; Jian Ni; Zhenfan Yang; Jianfang Xu

doi:10.18632/oncotarget.17913

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

EGFR G796D mutation mediates resistance to osimertinib

Di Zheng, Min Hu, Yu Bai, Xuehua Zhu, Xuesong Lu, Chunyan Wu, Jiying Wang, Li Liu, Zheng Wang, Jian Ni, Zhenfan Yang and Jianfang Xu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:49671-49679. https://doi.org/10.18632/oncotarget.17913

Metrics: PDF 3120 views | HTML 3981 views | ?

Abstract

Di Zheng1,*, Min Hu2,*, Yu Bai2, Xuehua Zhu2, Xuesong Lu3, Chunyan Wu4, Jiying Wang1, Li Liu1, Zheng Wang3, Jian Ni1, Zhenfan Yang2 and Jianfang Xu1

1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School, Shanghai, China

2IMED Asia, AstraZeneca, Shanghai, China

3Research and Development Information, AstraZeneca, Shanghai, China

4Department of Pathology, Shanghai Pulmonary Hospital, Tongji University Medical School, Shanghai, China

*These authors contributed equally to this work

Correspondence to:

Jianfang Xu, email: [email protected]

Zhenfan Yang, email: [email protected]

Keywords: EGFR, NSCLC, osimertinib, drug resistance, G796D

Received: March 08, 2017 Accepted: May 04, 2017 Published: May 16, 2017

ABSTRACT

Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound. Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification. However, a comprehensive view is still missing. In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism. Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17913

Publication Alerts

Research Papers:

EGFR G796D mutation mediates resistance to osimertinib

Abstract